Polymyalgia rheumatica

9 trials 1 recruiting MedDRA PT
9 Registered trials
1 Recruiting
7 Unique sponsors
7 Unique IMPs
3 Commercial trials
Drug classes (ATC)
— ATC code not specified 5
H Endocrinology (ATC H) 1
L Oncology (ATC L) 2
J Anti-infectives (ATC J) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 5 substances
Corticosteroid 1 substance
JAK inhibitor 1 substance
Phase III: 2 Phase II: 3 Phase IV: 3 Phase I (Other): 1

Filter these 9 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 9 trials

Phase III

2 trials
  • Centre Hospitalier Regional Et Universitaire De Brest Academic
    BARICITINIB
    2024-518385-26-01 1 country 2025 n=140
    Recruiting
  • Medical University Of Vienna Academic
    BARICITINIB
    2024-518556-22-00 3 countries 2022 n=46
    Ended

Phase II

3 trials
  • Sparrow Pharmaceuticals Inc. Commercial
    CLOFUTRIBEN; PREDNISOLONE
    2024-517406-29-00 2 countries 2022 n=72
    Ended
  • Synact Pharma ApS Commercial
    RESOMELAGON
    2026-525343-33-00 1 country n=60
    Pending
  • Universitair Medisch Centrum Groningen Academic
    (S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-CYANO-4,4-DIFLUOROPYRROLIDIN-1-YL)-2-OXOETHYLCARBAMOYL)-QUINOLIN-6-YL)(METHYL)AMINO)-PROPYL)PIPERAZIN-1-YL)-2-OXOETHYL)-68GA-[1,4,7,10]-TETRAAZACYCLODODECANE-1,4,7-TRIYL)TRIACETATE
    2024-511977-31-01 1 country n=30
    Pending

Phase IV

3 trials
  • Region Skane Academic
    RESPIRATORY SYNCYTIAL VIRUS, GLYCOPROTEIN F, RECOMBINANT, STABILISED IN THE PRE-FUSION CONFORMATION, ADJUVANTED WITH AS01E; RESPIRATORY SYNCYTIAL VIRUS, SUBGROUP A, STABILIZED PREFUSION F PROTEIN 847A, RESPIRATORY SYNCYTIAL VIRUS, SUBGROUP B, STABILIZED PREFUSION F PROTEIN 847B
    2024-518191-31-00 1 country n=180
    Pending
  • Sint Maartenskliniek Stichting Academic
    IMP not specified
    2024-513544-28-00 1 country 2023 n=114
    Ended
  • Sint Maartenskliniek Stichting Academic
    IMP not specified
    2024-513545-37-00 1 country 2023 n=174
    Ended

Phase I (Other)

1 trial
  • Sparrow Pharmaceuticals Inc. Commercial
    IMP not specified
    2023-507721-41-00 1 country 2024 n=14
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Sparrow Pharmaceuticals Inc. Commercial 2 Phase I (Other), Phase II 0
Sint Maartenskliniek Stichting Academic 2 Phase IV 0
Synact Pharma ApS Commercial 1 Phase II 0
Universitair Medisch Centrum Groningen Academic 1 Phase II 0
Centre Hospitalier Regional Et Universitaire De Brest Academic 1 Phase III 1
Medical University Of Vienna Academic 1 Phase III 0
Region Skane Academic 1 Phase IV 0
New trials by year
2022
2
2023
2
2024
1
2025
1
← All indication landscapes